Cosmetic Pigments Market worth $1.19 billion by 2031 - Exclusive Report by MarketsandMarkets™

MarketsandMarkets forecasts the global cosmetic pigments market to grow from $0.80 billion in 2026 to $1.19 billion by 2031, a 8.2% CAGR, supported by demand for premium color cosmetics and higher-performance formulations. Asia Pacific represented 43% of the market in 2026 and is projected to be the fastest-growing region, while nano pigments and lip makeup are expected to lead growth in their categories. Industry consolidation includes Global New Material's acquisition of Merck's Surface Solutions business and Sudarshan Chemical's acquisition of Heubach Group, alongside funding for bio-based pigment developers such as Sparxell ($3.2 million) and Octarine Bio ($5.8 million).

Analysis

This is not a standalone catalyst for the listed equities: the addressable niche is too small to alter consolidated earnings for diversified chemical groups. The investable implication is instead a mix shift toward treated, effect and bio-derived pigments, where qualification cycles and formulation know-how create higher switching costs than commodity colorants. Companies with proprietary dispersion, surface-treatment and regulatory-support capabilities can expand gross margin even if pigment volumes track only modestly above broader beauty demand.

LXS has the clearest indirect read-through via specialty additives and colorant-adjacent exposure, but the earnings sensitivity is likely immaterial absent disclosed cosmetic-care volumes, pricing, or capacity additions. MRK is a data-quality mismatch rather than a beneficiary: it is Merck & Co., not the former German Merck KGaA surface-solutions business referenced in the source. Do not infer a positive MRK thesis from this item. SXT's specialty ingredients platform could benefit at the margin from premium beauty innovation, but customer inventory normalization and raw-material pass-through matter far more than this market-growth estimate.

The more consequential second-order issue is consolidation: acquired pigment portfolios may rationalize capacity and raise pricing discipline in specialty grades, while lower-cost Chinese suppliers cap the ability to monetize standard organic pigments. Over 6-18 months, regulatory scrutiny of nano-material safety, microplastics and colorant traceability could favor scaled incumbents with documentation and approved-product libraries, but could also slow new-product adoption. The press-release forecast is vendor-sponsored and should be treated as directional, not as a demand estimate.

Contrarian view: premiumization is often mistaken for supplier pricing power. Beauty brands can preserve margin by reformulating, reducing pigment loading, dual-sourcing, or shifting promotional mix; supplier gains require evidence of sustained specialty-grade price increases rather than product-launch activity. The near-term signal is neutral, with no basis for a material rerating.

Key Decisions for Investors

• No new position from this release. Maintain neutral LXS and SXT until quarterly disclosures show specialty-pigment or personal-care sales growth materially above group growth, accompanied by gross-margin expansion; absent both, the theme is not investable.
• Place a research alert on LXS for announced capacity rationalization, specialty-colorant price increases, or cosmetic-care customer wins over the next 1-3 months. A confirmed 200-300bp segment-margin improvement would support a tactical long; a volume-led revenue gain without margin is not sufficient.
• Avoid using MRK as a proxy for cosmetic pigments; validate ticker/entity mapping before any trade. The relevant exposure described is associated with non-U.S. specialty-materials assets, not Merck & Co.'s pharmaceutical earnings stream.
• For a 6-18 month specialty-chemicals screen, favor firms demonstrating regulated nano/bio-pigment approvals and repeat formulation revenue over commodity pigment volume growth. Falsify the scarcity-margin thesis if Chinese export pricing falls materially or if major beauty customers disclose broad reformulation/dual-sourcing programs.